Page last updated: 2024-11-04

rofecoxib and Glioma

rofecoxib has been researched along with Glioma in 1 studies

Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)

Research Excerpts

Excerpt	Relevance	Reference
"A phase II trial was initiated to analyze the activity of continuously administered pioglitazone and rofecoxib combined with low-dose chemotherapy (capecitabine or temozolomide) in patients with high-grade gliomas (glioblastoma or anaplastic glioma)."	5.12	Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study. ( Baumgart, U; Bogdahn, U; Hau, P; Hirschmann, B; Kunz-Schughart, L; Muhleisen, H; Reichle, A; Ruemmele, P; Steinbrecher, A; Weimann, E, 2007)

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hau, P	1
Kunz-Schughart, L	1
Bogdahn, U	1
Baumgart, U	1
Hirschmann, B	1
Weimann, E	1
Muhleisen, H	1
Ruemmele, P	1
Steinbrecher, A	1
Reichle, A	1

Trials

1 trial available for rofecoxib and Glioma

Article	Year
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study. Oncology, 2007, Volume: 73, Issue:1-2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Capecitabin	2007